Prediabetes
Authors:
Hana Rosolová
Authors‘ workplace:
Centrum preventivní kardiologie LF UK v Plzni, 2. interní klinika FN Plzeň
Published in:
Vnitř Lék 2022; 68(2): 82-84
Category:
Main Topic
Overview
Prediabetes is defined as impaired fasting glucose or impaired glucose tolerance. It often appears as a part of metabolic syndrome and then represents high cardiometabolic risk. The cornestones of prediabetes management and Type 2 diabetes and cardiovascular disease prevention are weight reduction and regular physical activity. Suitable drugs for prediabetic patients are mentioned.
Keywords:
metabolic syndrome – prediabetes – type 2 diabetes prevention – atherosclerotic cardiovascular disease prevention – healthy life style
Sources
1. Perušičová J, Pelikánová T, Škrha M et al. za výbor ČDS. Doporučený postup péče o nemocné s prediabetem. DMEV 2012;15:20-22.
2. Diabetes Canada Clinical Practice Guidelines Expert Committee: Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2018;42:S10-S15.
3. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: A joint interim statement of the IDF Task Force on Epidemiology and Prevention; NHLBI, AHA, WHF, IAS, IASO. Circulation 2009;120:1640-1645.
4. Huang Y, Cai X, Mai W et al. Association between prediabates and risk of cardiovascular disease and all cause mortality. Systematic review and metaanalysis. BMJ 2016;355:i5953.
5. Warren B, Pankow JS, Matsushita K et al. Comparative prognostic performance of definitions of prediabetes. A prospective cohort analysis of the ARIC study. Lancet Diabetes Endocrinol. 2016;5:34-42.
6. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344:1343-1350.
7. Knowler WC, Fowler SE, Hamman RF et al. 10-year follow‑up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374:1677-1686.
8. Hamman RF, Wing RR, Edelstein SL et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006; 29:2102-2107.
9. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. EHJ 2021; doi:10.1093/eurheartj/ehab484.
10. Thomson EM: Air Pollution, Stress, and Allostatic Load: Linking Systemic and Central Nervous System Impacts. Journal of Alzheimer’s Disease. 69 (2019) 597-614.
11. Lilly M, Godwin M. Treating prediabetes with metformin: systematic review and meta‑analysis. Can Fam Physician. 2009;55:363-369.
12. DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
13. Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018 Jul;78(11):1113-1132.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 2
Most read in this issue
- Oral semaglutide – Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
- The position of SGLT2 inhibitors in current medical practice – update 2022
- Prediabetes
- Anticoagulation in cancer patients; new recommendations based on randomized clinical trials